Compare KNSL & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KNSL | ICLR |
|---|---|---|
| Founded | 2009 | 1990 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3B | 8.2B |
| IPO Year | 2016 | 2001 |
| Metric | KNSL | ICLR |
|---|---|---|
| Price | $327.51 | $102.04 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 13 |
| Target Price | ★ $403.45 | $178.62 |
| AVG Volume (30 Days) | 237.3K | ★ 992.7K |
| Earning Date | 04-23-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.31% | N/A |
| EPS Growth | ★ 21.77 | N/A |
| EPS | ★ 4.88 | N/A |
| Revenue | ★ $1,873,987,000.00 | N/A |
| Revenue This Year | $5.60 | N/A |
| Revenue Next Year | $7.88 | N/A |
| P/E Ratio | $70.35 | ★ $12.91 |
| Revenue Growth | ★ 18.04 | N/A |
| 52 Week Low | $321.97 | $66.57 |
| 52 Week High | $512.76 | $211.00 |
| Indicator | KNSL | ICLR |
|---|---|---|
| Relative Strength Index (RSI) | 34.58 | 39.35 |
| Support Level | $321.97 | $95.75 |
| Resistance Level | $364.61 | $114.75 |
| Average True Range (ATR) | 11.64 | 4.87 |
| MACD | -1.18 | -0.82 |
| Stochastic Oscillator | 13.65 | 13.20 |
Kinsale Capital Group Inc is an insurance holding company. The company is engaged in offering property, casualty, and specialty insurance products. It offers specialty insurance products for allied health, healthcare, life sciences, professional, and a public entity. The company operates in only one reportable segment which is the Excess and Surplus Lines Insurance segment, which includes commercial excess and surplus lines liability and property insurance products through its underwriting divisions. The company generates revenues in the form of premiums and investment income.
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.